
Many patients with cancer undergoing treatment incur a risk of cardiotoxicity, and these patients are not being made aware by physicians who may be unaware of the dangers themselves, according to a new study presented at the EuroHeartCare 2019, a scientific congress of the European Society of Cardiology (ESC).
“Depending on the type of chemotherapy and radiotherapy, between 1% and 25% patients [with cancer] may develop heart failure due to cancer treatment,” study author Robyn Clark, a professor at Flinders University in Adelaide, Australia, said in a press release. “Risk also depends on cardiovascular risk factors such as smoking and obesity. Better monitoring of the heart and intervention before, during, and after treatment can prevent or lessen the impact of this cardiotoxicity.”
As of 2012, more than 32 million people were living with cancer worldwide. As the number of cancer survivors rises and the number of patients >65 years old who require chronic cancer therapy grows, there is a need for more cardio-oncology services. These services are especially vital given that heart failure caused by cancer therapy can occur up to 20 years following treatment.